OS Therapies Incorporated (OSTX) AMEX
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
115 Pullman Crossing Road
Grasonville, MD 21638
United States of America (the)
Phone
410-297-7793
Website
Sector
Healthcare
Industry
Biotechnology
Employees
5
First IPO Date
August 01, 2024
| Name | Title | Pay | Year Born |
| Paul A. Romness | Founder, Chairman, President & Chief Executive Officer | 722,168 | 1966 |
| Christopher Acevedo | Chief Financial Officer | 36,000 | 1963 |
| Francis Knuettel | Chief Financial Officer | 36,000 | 1966 |
| Robert G. Petit | Chief Medical Officer & Chief Scientific Officer | 420,000 | 1960 |
| Kerry Clem | Chief Commercial Officer | 0 | 1970 |
| Gerald E. Commissiong | Chief Business Officer | 0 | 1982 |
| Jack Doll | Chief of Staff | 0 | N/A |
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Grasonville, Maryland.